Arbutus Biopharma Corporation (ABUS)
Last updated: 2026-10-20 17:19:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Arbutus Biopharma Corporation (ABUS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.29, with a market capitalization of $836.01M and a P/E ratio of 5.48. Over the past 52 weeks, its price has ranged from $3.50 to $5.45. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$836.01M | |
$4.24 | |
$12.60 | |
$0.82 | |
$4.23 | |
680.95K | |
4.85M | |
5.48 | |
$5.45 | |
$3.50 | |
-- | |
-- |
Arbutus Biopharma Corporation (ABUS) Stock Price Today
Arbutus Biopharma Corporation (ABUS) is currently trading at $4.29 as of 2026-10-20 17:17:00, up 1.30% ($0.05) from the previous close of $4.23
During today's regular trading session, ABUS has traded between $0.82 and $12.60, with a trading volume of 680.95K shares. The current price is near the lower end of today's range.
Arbutus Biopharma Corporation (ABUS) 7-Day Stock Price Change
Over the past seven days, Arbutus Biopharma Corporation (ABUS) moved from $4.22 to $4.29, representing a gain of 1.54% ($0.07).
The stock traded between $4.05 and $4.31 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 2.88 million shares, down versus the previous seven-day period, indicating lower trading activity.
ABUS 52-Week Price Position
Position in Range: 40.3%
ABUS is currently trading at $4.29, placing it 40.3% of the way from its 52-week low of $3.50 to its 52-week high of $5.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Arbutus Biopharma Corporation (ABUS)?
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Arbutus Biopharma Corporation Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 19 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Arbutus Biopharma Corporation (ABUS) Stock on MEXC
Eligible investors can buy real shares of Arbutus Biopharma Corporation (ABUS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Arbutus Biopharma Corporation (ABUS) stock price today?
2.Is ABUS stock going up or down today?
3.What is ABUS pre-market price?
4.What is ABUS after-hours price?
5.Is ABUS stock trading now?
6.Where does ABUS sit relative to its 52-week high and low?
7.What sector is Arbutus Biopharma Corporation in?
8.What is Arbutus Biopharma Corporation's market capitalization and where is it listed?
9.How is ABUS valued in terms of P/E ratio and EPS?
10.Does Arbutus Biopharma Corporation pay a dividend?
Explore More US Stocks
Search Stocks
ABUS Stock Calculator
Estimate the value between ABUS shares and USD.
ABUS Shares to USD
1.00 ABUS shares = 4.285 USD
Calculations are estimates based on the latest available price and are for reference only.


